In RA patients treated with TNF-α inhibitors, serum Th17-related cytokines decreased significantly in parallel with clinical remission in the responders, whereas increased percentage of Th17 cell and elevating related cytokine levels were found in non-responders [6, 7]. The gene discussed is TNF; the disease is rheumatoid arthritis.